Goldman Sachs Group Inc Theseus Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$0.0 - $4.08 $0 - $54,606
13,384 Added 78.81%
30,366 $0
Q4 2023

Feb 13, 2024
BUY
$2.12 - $4.18 $36,001 - $70,984
16,982 New
16,982 $68,000
Q2 2023

May 14, 2024
BUY
$7.28 - $11.82 $87,061 - $141,355
11,959 Added 70.42%
28,941 $270,000
Q2 2023

Aug 14, 2023
BUY
$7.28 - $11.82 $210,690 - $342,082
28,941 New
28,941 $270,000

Others Institutions Holding THRX

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Theseus Pharmaceuticals, Inc.

THRX Quotes by TradingView
  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email